Article Text

Download PDFPDF
Mass administration of azithromycin reduces childhood mortality in Niger
  1. Sarah Murphy1,
  2. Mehreen S Datoo2
  1. 1 Department of Paediatrics, Mercy University Hospital, Cork, Ireland
  2. 2 Nuffield Department of Medicine, Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Jenner Institute for Vaccine Research, Oxford, UK
  1. Correspondence to Dr Sarah Murphy, Department of Paediatrics, Mercy University Hospital, Cork T12 WE28, Ireland; sarah.murphy11{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Review of: Keenan JD, Arzika AM, Maliki R, et al. Longer-term assessment of azithromycin for reducing childhood mortality in Africa. N Engl J Med. 2019;380:2207–14.

Study design: This study, MORDOR II, is a continuation study of the MORDOR I trial. In MORDOR I, participants were randomised to receive either azithromycin or placebo biannually for 2 years. MORDOR II is an observational study specifically investigating the effect of subsequent administration of azithromycin to both the original placebo and azithromycin treatment arms of the trial in Niger for a further year. Therefore, participants were followed up for a total of 3 years. Participants and observers in this continuation study remained blinded to their original treatment arm from MORDOR I.

Patients: Infants and children (1–59 months of age) originally enrolled in MORDOR I in Niger, who had previously been randomised to receive either azithromycin or …

View Full Text


  • Contributors The abstract and commentary were written by both SM and MSD.

  • Provenance and peer review Not commissioned; internally peer reviewed.